Status:
COMPLETED
Irritability in Children With ADHD and Emotion Dysregulation
Lead Sponsor:
Tri-Service General Hospital
Conditions:
Irritable Mood
ADHD
Eligibility:
All Genders
6-18 years
Phase:
PHASE4
Brief Summary
Objective: Emotion dysregulation is common among children with ADHD and associated with a broad range of adult psychopathology, which is similar to the longitudinal outcomes of childhood irritability...
Detailed Description
Methods: A three-step, open-label, 10 week pilot study was conducted. Methylphenidate (4 weeks), aripiprazole (4 weeks), and the combination (2weeks) were examined in sequence as the treatment for ir...
Eligibility Criteria
Inclusion
- Patients aged 6 to 18 who have ADHD and emotion dysregulation, defined by the CBCL-Dysregulation Profile.
Exclusion
- Patients who are not willing to participate in the study after detailed explanation.
- Patients who have intellectual disability or could not follow the investigator's instructions.
- Patients who have severe neurological or mental illness like epileptic disorder, schizophrenia, bipolar disorder, or uncontrolled suicide risk.
- Patients who have severe medical illness or surgical conditions like uncontrolled abnormal thyroid function, or severe congenital heart disease.
- Patients who are allergic to methylphenidate or aripiprazole.
Key Trial Info
Start Date :
April 21 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 7 2022
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT05974241
Start Date
April 21 2017
End Date
April 7 2022
Last Update
August 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tri-Service General Hospital, National Defense Medical Center
Taipei, Taiwan, 114